Rhythm Pharmaceuticals (RYTM) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Rhythm Pharmaceuticals (RYTM) right now is Acquired hypothalamic obesity launch: The FDA approved IMCIVREE for acquired hypothalamic obesity in March 2026, and Rhythm reported more than 150 patient start forms within the first six weeks. Revenue (TTM) is ~$220M. If that keeps playing out, the setup is favourable; the risk to it is rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. No one can predict where RYTM trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Rhythm Pharmaceuticals (RYTM) higher?
1. Acquired hypothalamic obesity launch
The FDA approved IMCIVREE for acquired hypothalamic obesity in March 2026, and Rhythm reported more than 150 patient start forms within the first six weeks. This indication is meaningfully larger than the original ultra-rare genetic disorders and is the single biggest near-term driver of revenue growth.
2. Existing genetic obesity and BBS base
IMCIVREE continues to grow in its established indications, including Bardet-Biedl syndrome, with an increasing number of patients on reimbursed therapy globally. U.S. and international sales both contribute, giving the franchise a diversified, recurring commercial base to build on.
3. Bivamelagon and pipeline expansion
Bivamelagon, a next-generation oral MC4R agonist, showed statistically significant BMI reductions in a Phase 2 acquired hypothalamic obesity trial, and Rhythm aims to start a pivotal Phase 3 by the end of 2026. Success would extend the company's franchise with a convenient oral option and additional rare-obesity indications.
4. Global expansion of approvals
The European Commission granted marketing authorization for acquired hypothalamic obesity and a Japanese review is underway, adding international markets on top of the U.S. launch. Broader geographic reimbursement supports a longer runway of revenue growth for the core product.
What could weigh on RYTM?
Rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. It is not yet profitable and posts substantial quarterly net losses (around $56 million in the first quarter of 2026), so it relies on its cash balance (about $341 million as of the first quarter of 2026) and potential future financing. The valuation, with a market cap near $8 billion against roughly $220 million in trailing revenue, prices in aggressive future growth that may not materialize. Clinical trials such as the bivamelagon Phase 3 can fail, and the broader obesity market is dominated by far larger GLP-1 players like Novo Nordisk and Eli Lilly whose drugs could encroach on parts of Rhythm's niche.
Where RYTM trades today
A forecast starts from where the stock actually is. These are RYTM's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for RYTM as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a RYTM forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the RYTM guide and whether RYTM is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the RYTM outlook
The bottom line: what is driving Rhythm Pharmaceuticals (RYTM) is Acquired hypothalamic obesity launch, with revenue (ttm) at ~$220M. If that keeps playing out the setup is favourable; the risk is rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. No one can predict the price, so treat any RYTM forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around RYTM with Walnut
Use Rhythm Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Rhythm Pharmaceuticals (RYTM)?
+
No one can reliably predict where RYTM will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Rhythm Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive RYTM higher?
+
The main growth drivers are Acquired hypothalamic obesity launch; Existing genetic obesity and BBS base; Bivamelagon and pipeline expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to RYTM?
+
Rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. It is not yet profitable and posts substantial quarterly net losses (around $56 million in the first quarter of 2026), so it relies on its cash balance (about $341 million as of the first quarter of 2026) and potential future financing. The valuation, with a market cap near $8 billion against roughly $220 million in trailing revenue, prices in aggressive future growth that may not materialize. Clinical trials such as the bivamelagon Phase 3 can fail, and the broader obesity market is dominated by far larger GLP-1 players like Novo Nordisk and Eli Lilly whose drugs could encroach on parts of Rhythm's niche.
Will RYTM stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Rhythm Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is RYTM a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the RYTM "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.